Hospital

Although small intestinal bacterial overgrowth (SIBO) and irritable bowel syndrome (IBS) share many of the same symptoms, SIBO affects the small intestine and IBS affects the large intestine.

The application includes data from the Vivacity-MG3 study, demonstrating that individuals who received the drug had superior outcomes compared with the standard of care alone.

The findings further the understanding of respiratory virus immune evasion mechanisms and uncover how RSV-NS1 can target therapeutic intervention

Pharmacists can provide extra resources for patients, including explanations of the therapy options for the patients, the course of therapy, and what patients can expect.

Mirdametinib is an oral, allosteric small molecule MEK inhibitor to treat pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).

Eight areas of improvement were developed as part of national initiative with stakeholder involvement.

Accurate, effective screening is crucial for connecting patients with needed financial resources and support.

Despite evidence supporting the benefit of placing pharmacists in the ICU, there is still reluctance to widely adopt decentralized pharmacist models, largely due to immediate cost concerns and underrepresentation of pharmacy leaders in decision-making roles.

For pharmacies, AI and other technologies are key to thriving in the era of value-based care.

Pegcetacoplan is a targeted C3 therapy that is intended to regulate excessive activation of the complement cascade.

Pediatric patients weighing 20 kg to <50 kg should take 20 mg of apremilast twice daily and children weighing at least 50 kg should take 30 mg twice daily.

Let’s shine the spotlight on ourselves, and let’s begin to heal.

The proposed diagnostic agent has a long half-life, enables imaging the next day, and correlates to a longer shelf life in the pharmacy.

This designation follows the drug's rare pediatric disease designation in July 2024.

Investigators compare the impact of semaglutide for preserved ejection fraction and reduced ejection fraction, which both have different causes and responses to treatment.

Recognizing early signs and seeking medical care is essential for effective treatment and preventing long-term health complications.

The acceptance will lead to vaccines that provide better protection against the KP.2 strain of SARS-CoV-2.

The FDA assigned the combination a Prescription Drug User Fee Act goal date of April 21, 2025.

Individuals with chronic conditions like asthma, diabetes, and chronic obstructive pulmonary disease face an increased risk of developing RSV.

Communities that are impacted by increased wildfires can experience increased health risks, particularly among those who have asthma or chronic obstructive pulmonary disease.

Palliative care is crucial for safe and effective medication management to relieve symptoms and improve quality of life.

The use of intravenous immunoglobulin led to positive protective effects on osteoporosis.

The bispecific CAR T-cell therapy for treatment of multiple sclerosis is the first to target both CD19 and CD20.

Joseph Saseen offers valuable insights into the implications of the added performance and quality measures for patients and health care providers.

SMOs offer a range of services, including site selection, patient recruitment, data management, regulatory compliance, and quality assurance.

Propofol has a history of chronic shortage due to supply chain constraints.

Vimseltinib (Deciphera Pharmaceuticals) has a Prescription Drug User Fee Act goal date of February 17, 2025.

The drug is currently undergoing a phase 2 clinical trial for patient 12 years or older who are hospitalized with steroid-refractory acute graft-versus-host disease (aGVHD).

The highly potent, selective URAT1 inhibitor may help reduce serum uric acid levels and treat clinically visible tophi.